Pomalidomide (CAS 19171-19-8): A Superior Immunomodulator for Therapeutic Applications
Pomalidomide, identified by CAS 19171-19-8, stands out as a premier pharmaceutical intermediate, renowned for its potent immunomodulatory capabilities. This third-generation immunomodulatory drug (IMiD) is instrumental in the treatment of various hematological malignancies and other immune-related disorders. Its core function involves enhancing the efficacy of the immune system, particularly its T-cell and natural killer cell components, to combat disease. Additionally, Pomalidomide demonstrates a significant capacity to inhibit the proliferation of cancer cells and induce their programmed cell death (apoptosis), making it a critical component in advanced therapeutic strategies.
The applications of Pomalidomide are extensively documented in the treatment of multiple myeloma, a complex blood cancer, and certain forms of Kaposi sarcoma. Its efficacy in these areas underscores its importance as a key pharmaceutical intermediate. For organizations involved in the development and manufacturing of life-saving drugs, securing a reliable and high-quality source of Pomalidomide is paramount. NINGBO INNO PHARMCHEM CO.,LTD., a distinguished pharmaceutical intermediate manufacturer based in China, is dedicated to meeting this demand.
Our commitment extends to ensuring the highest standards of purity and consistency in our Pomalidomide production. This focus is critical, as the intermediate's quality directly correlates with the safety and effectiveness of the final therapeutic product. By providing a dependable supply of Pomalidomide, we aim to support the groundbreaking work of researchers and pharmaceutical companies globally.
The continuous pursuit of novel treatments for challenging diseases necessitates advanced pharmaceutical intermediates. Pomalidomide exemplifies this need, offering a powerful tool for immunomodulation and direct anti-tumor activity. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a trusted partner in this endeavor, contributing to the advancement of healthcare through the provision of superior quality chemical intermediates. Our expertise and dedication ensure that Pomalidomide remains accessible for critical therapeutic applications, aiding in the development of treatments that improve patient lives.
The applications of Pomalidomide are extensively documented in the treatment of multiple myeloma, a complex blood cancer, and certain forms of Kaposi sarcoma. Its efficacy in these areas underscores its importance as a key pharmaceutical intermediate. For organizations involved in the development and manufacturing of life-saving drugs, securing a reliable and high-quality source of Pomalidomide is paramount. NINGBO INNO PHARMCHEM CO.,LTD., a distinguished pharmaceutical intermediate manufacturer based in China, is dedicated to meeting this demand.
Our commitment extends to ensuring the highest standards of purity and consistency in our Pomalidomide production. This focus is critical, as the intermediate's quality directly correlates with the safety and effectiveness of the final therapeutic product. By providing a dependable supply of Pomalidomide, we aim to support the groundbreaking work of researchers and pharmaceutical companies globally.
The continuous pursuit of novel treatments for challenging diseases necessitates advanced pharmaceutical intermediates. Pomalidomide exemplifies this need, offering a powerful tool for immunomodulation and direct anti-tumor activity. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a trusted partner in this endeavor, contributing to the advancement of healthcare through the provision of superior quality chemical intermediates. Our expertise and dedication ensure that Pomalidomide remains accessible for critical therapeutic applications, aiding in the development of treatments that improve patient lives.
Perspectives & Insights
Alpha Spark Labs
“Our expertise and dedication ensure that Pomalidomide remains accessible for critical therapeutic applications, aiding in the development of treatments that improve patient lives.”
Future Pioneer 88
“Pomalidomide, identified by CAS 19171-19-8, stands out as a premier pharmaceutical intermediate, renowned for its potent immunomodulatory capabilities.”
Core Explorer Pro
“This third-generation immunomodulatory drug (IMiD) is instrumental in the treatment of various hematological malignancies and other immune-related disorders.”